

Webinar on IMI 2 – Call 20 topic Innovations to accelerate vaccine development and manufacture

Participant list

27.01.2020

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
bruno	alfonsi	bionet	Italy	bruno.a@bionet-asia.com	Experience of over 35 years in the Human Vaccine field
Arno	Andeweg	ErasmusMC	Netherlands	a.andeweg@erasmusmc.nl	Immune repertoire analysis to support vaccine design and evaluation
Elisa	Argüelles Enjuanes	IMPULSO INDUSTRIAL ALTERNATIVO	Spain	elisa.argueles@impulso.es	N/A
Meritxell	Ascanio	BCN Health Economics & Outcomes Research S.L.	Spain	meritxell.ascanio@bcnhealth.com	Design and conduct cost-effectiveness analysis, economic evaluations of observational/retrospective data sets, medical writing
Alexander	Batista Duharte	Dpto Farmacología, Facultad de Medicina, Universidad de Valencia.	Spain	batistaduharte@gmail.com	Improvement of vaccine immunogenicity/efficacy/safety using antisense oligonucleotides

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
anne-sophie	beignon	cnrs	France	anne-sophie.beignon@cea.fr	vaccinology preclinical studies, vaccines MOA
Laurent	BELOEIL	BIOASTER	France	laurent.beloeil@bioaster.org	Vaccines and adjuvants, immunology, OMIC technologies, data analysis
SARRA	BEN ATTIA	Luxembourg Institute of Health	Luxembourg	benattia.sarra@yahoo.fr	NA
Charles	Betz	Luxinnovation	Luxembourg	charles.betz@luxinnovation.lu	Link to Luxembourgish health system and research ecosystem
Rosa M ^a	Bolea	Research Centre for Prions and Emerging Diseases - University of Zaragoza	Spain	rbolea@unizar.es	Working in Microbiology, Genetics and Animal Pathology, infectious diseases such as prions, C.Difficile, Salmonella,etc. P3 faci
Luisa	Borgianni	Sclavo Vaccines Association	Italy	borgianni@sclavo.org	Management, Dissemination and Impact Assesment
Marieke	Bruinsma	Mimetas - the Organ-on-a-chip company	Netherlands	m.bruinsma@mimetas.com	High-throughput microfluidic 3D human biological and disease models

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
Jennifer	Byrne	NIBRT	Ireland	jennifer.byrne@nibr.ie	NIBRT research teams provide in depth understanding of the challenges and opportunities around the manufacture of biologics
Raquel	Carnero		Spain	carneroraquel@gmail.com	Vaccine divulgation projects in Spain, author of the book Vacunando. Dos Siglos y Sumando! /Vaccinating. Two Centuries and Beyond
Miguel	Casanovas	Inmunotek	Spain	mcasanovas@immunotek.com	expertise in targeting trained immunity
Corentin	Chaboud	BIOASTER	France	corentin.chaboud@bioaster.org	omics technologies knowledge-management systems for data integration, experience in vaccines private-public projects (incl IMI)
Romulus	CHEVERESAN	BEIA Consult International	Romania	romulus.cheveresan@beia.ro	Project Management activities
Eve	Chevillard	Inserm	France	eve.chevillard@inserm.fr	European management expertise, human resources and high containment facility
Christopher	Chiu	Imperial College London	United Kingdom	c.chiu@imperial.ac.uk	Experience and capacity in controlled human infection models of influenza and RSV; human and mucosal immunity expertise
Annalisa	Ciabattini	University of Siena	Italy	annalisa.ciabattini@unisi.it	Immunology expertise; Computational multiparametric flow cytometry data analysis
Paul	Collins	Spurn Bird Observatory	Uruguay	PCNFA@HOTMAIL.COM	What we do with help from Hull University is sample wild birds for bird flu viruses

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
Antonella	Conforti	Evvivax	Italy	conforti@evvivax.com	Our company is expert in developing genetic antitumoral vaccines both for humans and animals
Rodrigo	Correa-Oliveira	Fiocruz	Brazil	rodrigo.correa@fiocruz.br	I have expertise and can help on the development of programs in Brasil.
Rebecca	Cox	University of Bergen	Norway	rebecca.cox@uib.no	Large Biobanks of human samples
Francis P.	Crawley	GCPA & SIDCER	Belgium	fpc@gcpalliance.org	Member, IMI Pool of Patient Experts. Ethics Advisor and/or Data Protection Officer on IMI(1&2) and European Commission Projects
MARIA GRAZIA	CUSI	UNIVERSITY OF SIENA	Italy	cusi@unisi.it	Expertise in viral immunology, innate, humoral and cellular immunity, viral vectors, respiratory viruses infection in vitro
Dobрева	Dafina	FISABIO	Spain	dafina.dobрева@gmail.com	expertise in epidemiology of infectious diseases, observational studies and randomized clinical trials
Sharon	Davin		Ireland	sharon.davin@approcess.com	Expertise in scale-able process development for vaccine manufacture
ingrid	de Visser - Kamerling	Centre for Human Drug Research	Netherlands	ldvisser@chdr.nl	scientific expertise and execution of the clinical trial
Mara	Diaconu	Norwegian University of Science and	Norway	mara.diaconu@ntnu.no	Expertise in IMI, leading research in field, clinical trials, HUNT study data and other data set

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
		Technology, Faculty of Medicine and Health Sciences			
Javier	Diez-Domingo	FISABIO	Spain	jdiezdomingo@gmail.com	Large experience in IMI projects. Research team with different areas of expertise: vaccines, clinical trials, ethics, RWE, etc.
Song	Ding	EuroVacc Foundation	Netherlands	song.ding@eurovacc.org	Vaccine development
Alexandre	Dobly			alexandre.dobly@sciensano.be	Regulatory expertise, samples
Camilla	Foged	University of Copenhagen	Denmark	camilla.foged@sund.ku.dk	Expert knowledge about vaccines
LEONIDAS	FOTIADIS	AKESO - Panhellenic Organization for patient with Autoimmune Rheumatic Diseases	Greece	fotiadisleonidas@gmail.com	unmet needs of patients with autoimmune diseases

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
Marco	Fragai	University of Florence and Magnetic Resonance Center (CERM)	Italy	fragai@cerm.unifi.it	NMR characterization of proteins adsorbed on adjuvants in vaccine formulations; Expression of isotopically enriched proteins
Marcus	Furch	Rodos Biotarget GmbH	Germany	m.furch@biotargeting.eu	vaccine asset in preclinical development
nathalie	garcon	BIOASTER	France	nathalie.garcon@bioaster.org	vaccinology from research to development, system vaccinology, related technologies omics, data analysis, microfluidics,
ambre	gelley		France	ambre.gelley@u-bordeaux.fr	pharmacist specialised in MTI, I work in the clinical research and i'm interested in this subject
Thiry	Georges	SAS Senergues	France	georgesthiry@senerguesconsult.com	Overall expertise in vaccine development, process development / CMC and Project management
AFRICA	GONZÁLEZ FERNÁNDEZ	UNIVERSITY OF VIGO	Spain	africa@uvigo.es	Expertise in basic and applied Immunology (MD, PhD, Immunologist); Expert in Vaccines, Nanovaccines, Toxicity to nanomaterials.
Natalie	Gordon	Bar Ilan University	Israel	natalia.gordon@biu.ac.il	vaccine development
Gunnveig	Grodeland	University of Oslo	Norway	gunnveig.grodeland@medisin.uio.no	Vaccine development, predictions of vaccine efficacy

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
Noreen	Grünauer	TU Graz (Institute of Process and Particle Engineering)	Austria	noreen.gruenauer@rce.at	WP5 In silico biomanufacturing - T5.2 Bioprocess scale-up/scale-down models (Lead)
Heidi	Gruner	Centro hospitalar universitário Lisboa central.	Portugal	heidi.ml.gruner@gmail.com	Expertise and patient monitorization in outpatient clinic or on a Ward
Carlos	Guzman	HZI	Germany	CarlosAlberto.guzman@helmholtz-hzi.de	preclinical models, immuno monitoring (preclinical studies, humans), cohorts of vulnerable individuals
Ellen	Hubin	Modis	Belgium	ellen.hubin@modisbelgium.be	Project Management/Writing Consultancy
ANKE	HUCKRIEDE	UNIVERSITY MEDICAL CENTER GRONINGEN	Netherlands	a.l.w.huckriede@umcg.nl	human 'immunology-in-a-dish' models; human biobanks with longitudinal samples of children, adults, elderly; influenza expertise
Andreia	Jesus			andreia.jesus@glintt.com	Glintt is a technology and consultancy multinational focused on healthcare solutions for hospitals and pharmacies
Stefan	Jungbluth			stefan.jungbluth@eu.vaccine.eu	Vaccine development expertise
Bernhard	Kerscher	Paul-Ehrlich-Institut	Germany	bernhard.kerscher@pei.de	non-clinical vaccine assessment; experimental quality control testing of vaccines;

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
Eanna	Kiely	ClinBuild	Germany	eanna.kiely@clinbuild.com	CDISC standards author/trainer/consultant experience in vaccines. Standards are a core HMA/EMA Big Data and H2020 recommendation
Donal	Killackey	SSPC Pharmaceutical Research Centre	Ireland	donal.killackey@ul.ie	Advanced manufacturing in pharmaceuticals; process modelling; formulation; catalysis.
Boaz	Kogon	RMIT Europe	Spain	boaz.kogon@rmit.edu.au	Strong research expertise in various aspects of vaccine development.
Maryse	Letiembre	Institute for Research in Biomedicine (IRB)	Switzerland	maryse.letiembre@irb.usi.ch	The Institute for Research in Biomedicine is internationally recognized as a centre of competence in human immunology.
Diletta	Magini	Sclavo Vaccines Association	Italy	magini@fondazione sclavo.org	Expertise in management, dissemination and impact assessment activities.
Sara	Mangsbo	Uppsala University	Sweden	sara.mangsbo@farm bio.uu.se	Immuno-oncology and cancer vaccine development expertise
Jacqueline	Marovac	Jadran Clinical	Croatia	jmarovac@gmail.com	Offer Project Management services, Clinical Trial Management Services
Carlos	Martin	Universidad de Zaragoza (Spain)	Spain	carlos@unizar.es	Developer of a new live attenuated TB vaccine candidate (MTBVAC) University of Zaragoza . Industrial Partner BIOFABRI

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
Donata	Medaglini	University of Siena/Sclavo Vaccines Association	Italy	medaglini@sclavo.org	Systems biology, analysis of the immune response, transcriptomic analysis, in vitro mucosa models, management and coordination
Irina	Meln	EVI	Germany	irina.meln@eu-vaccine.eu	coordination
Ainara	Mira-Iglesias	FISABIO-Public Health	Spain	mira_ain@gva.es	6 years of experience in vaccine research, coordinating a surveillance network for the study of influenza vaccine effectiveness
Chiara	Morandi	Sclavo Vaccines Association	Italy	morandi@sclavo.org	Management, dissemination and impact assessment
Constanza	Niell	DiabetesCERO	Spain	constanzaniell@gmail.com	I am a carer of my daughter with Diabetes T1. I am an EC Independent Expert in other areas as well. Resourceful and proactive.
Nicolas	Noulin	hVIVO	United Kingdom	n.noulin@hvivo.com	We would bring our expertise in CHIM studies (subtopic 2), vaccine testing and clinical trials
Erik	Nygren	RISE Research Institutes of Sweden	Sweden	erik.nygren@ri.se	Expertise and ongoing activities in multiple areas relating to biologics e.g. pre-clinical testing, formulation, safety etc
Alejandro	Orrico Sánchez	Fisabio	Spain	orrico_ale@gva.es	We currently coordinate one IMI project and participate in other 2 IMI projects

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
Anton	OTTAVI	Inserm/Inria	France	anton.ottavi@u-bordeaux.fr	High dimensional immunological data analysis and mathematical modelling
Giorgia	Pallafacchina	CNR and University of Padua	Italy	giorgia.pallafacchina@unipd.it	Knowledge and expertise about mitochondrial signaling and metabolism
Fabio	Palombo	Takis	Italy	fabiopalombo.rm@gmail.com	We are developing a fast track GMP facility for genetic vaccine, my groups contributed extensively in this field
maria	pedersen	Permanent EU Representation Region of Central Denmark	Denmark	mhp@centraldenmark.eu	Qualified partners
CECILE	PELTEKIAN	Intitut Pasteur	France	cecile.peltekian@pasteur.fr	At this stage, attending to the webinar to have a clear overview of the call. Our institute has expertise in vaccinology
Lina	Pérez-Breva	Vaccine Research-FISABIO Public Health	Spain	linaperezbreva@gmail.com	MD,PHD , Vaccine Research Department. In charge of Clinical trials Department. Also observational studies, healthcare databases.
Daraporn	Pittayakhajonwut	BioNet-Asia	Thailand	daraporn.p@bionet-asia.com	Optimize upstream and downstream processes, develop analytical test for quality control of vaccine development

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
Beia	POC			beiapoc2017@gmail.com	new fields to be added in the projects
Rofagha	Rofagha	Schuttelaar & Partners	Belgium	bea.rofagha@gmx.net	Societal impact studies, communication expertise (incl. strategy, website, videos, events, social media), project management
Ombeline	Rossier	University Paris-Saclay	France	ombeline.rossier@u-psud.fr	Virus-like-particles (VLP) for vaccine development
Nadia	Rozendaal	Human Vaccines Project Europe	Netherlands	nrozendaal@humanvaccinesproject.org	Decoding the human immune system to accelerate the development of vaccines, immunotherapies to prevent/treat important diseases
Chen	Sagiv			chen@deepathology.ai	AI
Antoine-Emmanuel	Saliba	Helmholtz Institute for RNA-based infection research (HIRI)	Germany	emmanuel.saliba@helmholtz-hiri.de	Expertise/ressources: single-cell multi-omics; time-resolved single-cell; data analysis
maria grazia	santagati		Italy	mariagrazia.santagati@tin.it	Scientific consultancy
Ted	Schenkelberg	Human Vaccines Project	United States	tschenkelberg@humanvaccinesproject.org	Decode the human immune system to accelerate the development of vaccines, immunotherapies to prevent/treat important diseases

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
Magnus	Seierstad	University of Oslo, Faculty of Medicine	Norway	magnseie@uio.no	The adviser team will bring administrative coordination of a WP and the research team research expertise on vaccines
Dolores	Serrano	Universidad complutense de madrid	Spain	drserran@ucm.es	Continuous manufacturing
Eloisa	Sevilla	Research Centre for Prions and Emerging Diseases - University of Zaragoza	Spain	eloisa_sr@hotmail.com	Working in Microbiology, Genetics and Animal Pathology, infectious diseases such as prions, C.Difficile, Salmonella,etc. P3 faci
nir	shaled	ISERD	Israel	nir.s@iserd.org.il	NCP
Hugo	Soares	iBET	Portugal	hsoares@ibet.pt	iBET has coordinated H2020 DIVINE project - simplifying Vaccine Purification - Continuous and Affinity chromatography
Montserrat	Sole	Institut Biotecnologia i Biomedicina	Spain	montserrat.sole.castellvi@uab.cat	Immunology expertise, antigen search, lymphocytes activation, protein characterisation
Marco	Soriani	Reithera Srl	Italy	marco.soriani@reithera.com	We own a vaccine technology platform that may advance the field of infectious diseases.

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
Benoit	SOUBEYRAND	Blossom Vaccinology	France	bs@blossomvaccinology.com	I was responsible for the medical activities within a vaccine company during 30 years.
George	Suciu	BEIA Consult International	Romania	george@beia.ro	IoT telemetry, cloud computing, experience in over 40 R&D projects www.beia.eu
Anna	Sumeray	Virometix	Switzerland	annasumeray@virometix.com	Experience sharing of own vaccine development
Roisin	Thompson	Centre for Process Innovation	United Kingdom	roisin.thompson@uk-cpi.com	CPI is a UK research organisation with expertise in biologics production, including bioprocessing, analysis and formulation
Claudia	Trombetta	University of Siena	Italy	trombetta@unisi.it	Influenza vaccines, influenza viruses, serological assays, seroepidemiological studies
D.B.R.K. Gupta	Udatha	Oslo Cancer Cluster	Norway	gupta.udatha@oslocluster.no	Project Management, Events, Workshops, Networking, Communication and Dissemination
Mariagrazia	Uguccioni	Institute for Research in Biomedicine	Switzerland	uguccioni@irb.usi.ch	The study of responses to chemokine receptors, and methods to modify them, in patients experiencing chronic immune activation
Debbie	van Baarle	National Institute for Health and the Environment (RIVM)	Netherlands	debbie.van.baarle@rivm.nl	epithelial models host-pathogen interaction, Immunology of virus infections and vaccination, vaccination study in age groups

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
Frans	van den Boom	Human Vaccines Project Europe	Netherlands	fvandenboom@humanvaccinesproject.org	Decoding the human immune system to accelerate the development of vaccines, immunotherapies to prevent,treat important diseases
Silvia	Vendetti	Istituto Superiore di Sanità	Italy	silvia.vendetti@iss.it	Experience in immune regulation and vaccine/adjuvants immune responses. New strategies of vaccination.
Alessandra	Veronese	Accademia dei Pazienti (EUPATI Italy)	Italy	veronal2710@gmail.com	I can bring my expertise either as Expert Patient EUPATI Italy, or as Clinical Research Expert with 20 years of experience
Alessandra	Vitelli	ReiThera Srl	Italy	alessandra.vitelli@reithera.com	ReiThera Srl has a long standing expertise in the field of viral vectored vaccine, In addition the company has a GMP facility
Antonia	Volny-Luraghi	Modis	Belgium	antonia.volny-luraghi@modisbelgium.be	Project Management /Writing Consultancy
Gabriele	Wagner	ARTTIC	Germany	wagner@arttic.eu	long-standing consultancy expertise in IMI proposal development, project management and dissemination service
John	Walsh	British heart Foundation, Swindon Healthwatch,	United Kingdom	bon.john@ntlworld.com	Public acceptance of vaccination and other public health programmes

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities
Sabrina	Welsh	Human Vaccines Project	United States	swelsh@humanvaccinesproject.org	The Human Vaccines Project brings expertise in OMICs, systems serology, T and B cell repertoire, and computational biology.
Wassana	Wijagkanalan	BioNet-Asia Co., Ltd.	Thailand	wassana.w@bionet-asia.com	vaccine R&D, regulatory, clinical development, project management
Emre	YARCI	Association of Research-Based Pharmaceutical Companies (AIFD)	Turkey	emre.yarci@aifd.org.tr	Network facilitation
İlker	Yeşilkaya	DNB (Decision & Behaviour Analytics LLC.	Turkey	ilkeryesilkaya@dnbanalytics.com	AI- based clinical behavioral research platform focused on psychiatric disorders